Ziprasidone hydrochloride是一种口服活性的5-HT与多巴胺受体拮抗剂,能高效拮抗5-HT2A、D2及5-HT1A受体。
|
英文别名 (English Synonym) |
Ziprasidone hydrochloride monohydrate |
|
中文名称 (Chinese Name) |
盐酸齐拉西酮水合物 |
|
靶点 (Target) |
5-HT Receptor |
|
通路 (Pathway) |
Neuroscience |
|
CAS号 (CAS NO.) |
138982-67-9 |
|
分子式 (Formula) |
C21H24Cl2N4O2S |
|
分子量 (Molecular Weight) |
467.41 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001 Aug 17,425(3):197-201. doi: 10.1016/s0014-2999(01)01188-8. PMID: 11513838.[2]Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct,275(1):101-13. PMID: 7562537.
